



HEME BIOSYNTHESIS IN ERYTHROID CELLS:

Transcriptional Regulation of the Human 5-Aminolevulinate Synthase 2 Gene

A thesis submitted to the University of Adelaide
for the degree of Doctor of Philosophy

by

Katharina Helen Surinya B.Sc. Hons (University of Adelaide)

Department of Biochemistry

University of Adelaide

Adelaide, South Australia.

August, 1997

TABLE OF CONTENTS

THESIS SUMMARY	viii
DECLARATION	x
ACKNOWLEDGEMENTS.....	xi
ABBREVIATIONS.....	xiii

CHAPTER ONE : GENERAL INTRODUCTION

1.1 INTRODUCTION	1
1.2 HEMATOPOIESIS	2
1.3 ERYTHROPOIESIS.....	3
1.3.1 <i>In vitro</i> Models of Erythroid Differentiation.....	5
1.3.2 Regulation of the Synthesis of Erythropoietin (Epo).....	6
1.4 SYNTHESIS OF HEMOGLOBIN.....	8
1.4.1 Regulation of the Intracellular Levels of Iron	8
1.4.2 The Globin Gene Cluster	12
1.4.3 Regulation of Globin Gene Expression.....	14
1.5 <i>TRANS</i> -ACTING FACTORS INVOLVED IN ERYTHROID-SPECIFIC GENE EXPRESSION	18
1.5.1 GATA-1.....	18
1.5.2 NF-E2	22
1.5.3 EKLF	24
1.5.4 Thyroid Hormone Receptor:.....	26
1.5.5 Ets Gene Family of Transcription Factors	29
1.5.6 SCL and Rbtn2.....	31
1.6 THE HEME BIOSYNTHETIC PATHWAY	32
1.7 ALAS	34
1.7.1 Structure and Properties of ALAS	34
1.7.2 Isozymes of ALAS	34
1.7.3 Structural Organisation of the ALAS1 and ALAS2 Genes.....	36

1.8 REGULATION OF ALAS1 GENE EXPRESSION IN HEPATIC TISSUE.....	38
1.8.1 Transcriptional Regulation of the ALAS1 Gene	38
1.8.2 Regulation of the ALAS1 Gene by Heme.....	40
1.9 REGULATION OF ALAS2 GENE EXPRESSION IN ERYTHROID TISSUE.....	43
1.9.1 Transcriptional Regulation of the ALAS2 Gene	43
1.9.2 Post-transcriptional Regulation of the ALAS2 Gene.....	47
1.10 OTHER ENZYMES OF THE HEME BIOSYNTHETIC PATHWAY.....	48
1.11 ROLE OF HEME IN THE REGULATION OF HEMOGLOBIN SYNTHESIS.....	53
1.11.1 Regulation of ALAS2 by Heme.....	54
1.11.2 Translation of Globin is Regulated by Heme.....	54
1.12 DISEASES RELATED TO HEME BIOSYNTHESIS	55
1.12.1 Sideroblastic Anemias	56
1.13 AN <i>IN VITRO</i> MODEL TO INVESTIGATE ERYTHROID-SPECIFIC GENE EXPRESSION	58
1.14 AIMS OF THIS THESIS	60

CHAPTER TWO: MATERIALS AND METHODS

2.1 MATERIALS	62
2.1.1 Drugs, Chemicals and Reagents	62
2.1.2 Radiochemicals	62
2.1.3 Enzymes	63
2.1.4 Buffers	63
2.1.5 Cloning Vectors.....	64
2.1.6 Cloned DNA Sequences	64
2.1.7 Synthetic Oligonucleotides.....	65
<i>i) Oligonucleotides for sequencing plasmid constructs.....</i>	65
<i>ii) Oligonucleotides for the generation of ALAS2/reporter gene constructs.....</i>	65
<i>iii) Oligonucleotides used for Site-directed Mutagenesis</i>	66
<i>iv) Sequences of the Sense Strand of Synthetic Oligonucleotides used in Gel Shift Assays</i>	67
2.1.8 Bacterial Strains.....	69
2.1.9 Bacterial Growth Media.....	70

2.1.10 Tissue Culture Cell Lines and Media	71
<i>i) Cell lines</i>	71
<i>ii) Solutions</i>	71
<i>iii) Media</i>	71
2.1.11 Miscellaneous	72
2.2 RECOMBINANT DNA METHODS	72
2.2.1 General DNA Methods	72
2.2.2 Plasmid DNA Preparation.....	72
2.2.3 Restriction Enzyme Digestions of DNA.....	73
2.2.4 Preparation of Cloning Vectors.....	73
2.2.5 Preparation of DNA Restriction Fragments.....	73
2.2.6 Ligation of DNA.....	74
2.2.7 Transformation of <i>E. coli</i> with Recombinant Plasmids.....	74
<i>i) Preparation of Competent E. coli</i>	74
<i>ii) Transformation of Competent Bacteria</i>	75
2.2.8 Dideoxy-Chain Sequencing Analysis	76
2.2.9 Gel Electrophoresis of DNA for Sequence Analysis	76
2.2.10 Preparation of Radiolabelled DNA Probes.....	76
<i>i) Oligo-Labelling of DNA</i>	76
<i>ii) 5' End-Labelling of Synthetic DNA oligonucleotides</i>	77
2.2.11 Oligonucleotide Site-Directed Mutagenesis	77
<i>i) Preparation of Single-Stranded DNA</i>	77
<i>ii) Synthesis of the Mutagenic DNA strand</i>	78
2.2.12 Colony Screening.....	79
2.3 POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION OF DNA	80
2.4 SYNTHESIS OF PLASMID CONSTRUCTS.....	81
2.4.1 Construction of ALAS2 Promoter/Reporter Gene Plasmids	81
2.4.2 Construction of ALAS2 Intron and 3'-Flanking/Reporter Gene Plasmids	83
<i>i) Synthesis of ALAS2 intron and 3'-flanking constructs fused to the human ALAS2 promoter</i>	83
<i>ii) Synthesis of ALAS2 intron constructs fused to the heterologous thymidine kinase promoter</i>	85

2.4.3 Construction of Human ALAS2 Intron 8 Deletion/Reporter Gene Plasmids	86
2.4.4 Site-directed Mutagenesis of the Human ALAS2 Intron 8 Sequence	87
2.4.5 Synthesis of Plasmid Constructs for use in Transactivation Assays	87
2.5 METHODS FOR THE <i>IN VITRO</i> DIFFERENTIATION OF ERYTHROID CELL LINES	89
2.5.1 Cell Maintenance	89
2.5.2 <i>In vitro</i> Differentiation of Erythroid Cell Lines	90
i) <i>Dimethyl sulfoxide (Me₂SO)-induced differentiation of MEL cell lines</i>	90
ii) <i>Hemin-induced differentiation of the K562 cell line</i>	90
iii) <i>Staining of cells with 2,7 diaminofluorene (DAF), an indicator of hemoglobin synthesis</i>	90
2.6 METHODS FOR EXPRESSION OF PROMOTER CONSTRUCTS IN TISSUE CULTURE CELL LINES.....	91
2.6.1 Transfection of Erythroid MEL Cell Lines by Electroporation.....	92
i) <i>Transient transfection of the erythroid MEL F4-12B2 cell line</i>	92
ii) <i>Stable transfection of the erythroid MELC 707T cell line</i>	92
2.6.2 Transient Transfection of the K562 Cell Line by Electroporation	93
2.6.3 Transient Transfection of the COS-1 or CV-1 Cell Lines by Electroporation.....	93
2.6.4 Reporter Gene Assays.....	94
i) <i>Bradford Protein Assay</i>	94
ii) <i>Assay for Luciferase Activity</i>	94
iii) <i>Assay for β-galactosidase Activity</i>	95
iv) <i>Assay for Chloramphenicol Acetyltransferase (CAT) Activity</i>	95
2.7 METHODS FOR ISOLATION AND ANALYSIS OF RNA.....	96
2.7.1 Isolation of RNA from Tissue Culture Cells	96
2.7.2 Northern Hybridisation Analysis of RNA	96
i) <i>Northern Blots</i>	96
ii) <i>Removal of Probe from Filter</i>	96
2.8 SOUTHERN BLOT ANALYSIS AND HYBRIDISATION CONDITIONS.....	97
2.8.1 Isolation of Genomic DNA from Tissue Culture Cells	97
2.8.2 Southern Blot Analysis	97

2.9 METHODS FOR GEL SHIFT ASSAYS	98
2.9.1 Preparation of Nuclear Protein Extracts	98
2.9.2 Preparation of Radiolabelled Annealed Oligonucleotide Probes	99
2.9.3 Gel Shift Assay	99
2.10 MISCELLANEOUS METHODS.....	100
2.10.1 Densitometric Quantitation of Bands on Autoradiograms	100
2.10.2 Computer Analysis.....	101

**CHAPTER THREE: EVALUATION OF ERYTHROID CELL LINES SUITABLE
FOR TRANSIENT TRANSFECTION STUDIES AND
SYNTHESIS OF A STABLY TRANSFECTED MEL CELL LINE**

3.1 INTRODUCTION	102
3.2 RESULTS	103
3.2.1 Northern Blot Analysis of MEL Cell Lines Chemically Induced to Differentiate <i>in vitro</i>	103
3.2.2 Optimisation of Transient Transfection of Erythroid MEL Cell Lines	104
3.2.3 Generation of a Stably Transfected MEL Cell Line: Determination of Selection Conditions.....	106
3.2.4 Generation of MEL Cell Line Stably Transfected with a 1.9kb ALAS2 Promoter/CAT Reporter Construct.....	106
3.2.5 Detection of the Luciferase Reporter Gene in an Adherent MEL Cell Line and Northern Blot Analysis of this Cell Line Induced to Differentiate with Me ₂ SO	110
3.2.6 An Investigation into the Suitability of the Erythroid J2E and K562 Cell Lines for Transient Transfection Studies.....	112
3.3 DISCUSSION	113

**CHAPTER FOUR : TRANSIENT TRANSFECTION STUDIES OF THE ALAS2
5'-FLANKING AND INTRONIC REGIONS ON THE
TISSUE-SPECIFIC EXPRESSION OF THE ALAS2 GENE**

4.1 INTRODUCTION	118
4.2 RESULTS	119
4.2.1 Analysis of the 5'-Flanking Region of the Human ALAS2 Gene	119

4.2.2 Analysis of Other Potential Regulatory Regions of the Human ALAS2 Gene ..	120
4.2.3 Transactivation of Human ALAS2/Luciferase Reporter Gene Constructs by GATA-1	123
4.3 DISCUSSION	125

**CHAPTER FIVE : IDENTIFICATION OF REGULATORY ELEMENTS AND
CORRESPONDING TRANSCRIPTION FACTORS THAT DRIVE
EXPRESSION OF THE ALAS2 PROMOTER**

5.1 INTRODUCTION	133
5.2 RESULTS	135
5.2.1 Analysis of Putative GATA-1 Binding Sites in the Human ALAS2 Promoter ..	135
i) <i>GATA-1 Protein Binds at -124 and -100 GATA Sites in the Promoter</i>	135
ii) <i>GATA-1 protein and TBP Bind to the -27 Site</i>	136
iii) <i>Mutational Analysis of the GATA-1 Binding Sites</i>	138
iv) <i>GATA-1 Transactivates the ALAS2 Promoter in Non-erythroid Cells</i>	139
5.2.2 Analysis of a Putative CACCC Sequence in the Human ALAS2 Promoter	140
i) <i>Sp1, EKLf and BKLf bind to the CACCC Sequence</i>	140
ii) <i>Mutational Analysis of the CACCC Sequence</i>	142
iii) <i>Attempts to Identify the Transcriptional Activator at the -54 CACCC Site</i>	142
5.2.3 Analysis of a Putative NF-E2-like Sequence in the Human ALAS2 Promoter	148
i) <i>Gel Shift Analysis of an NF-E2-like Sequence</i>	148
ii) <i>Mutational Analysis of the Putative NF-E2 Binding Site</i>	149
5.2.4 Analysis of a Putative Thyroid Hormone Receptor Binding Site (TRE) in the Human ALAS2 Promoter	150
i) <i>Gel Shift Analysis of a Putative Thyroid Hormone Receptor Binding Site</i>	150
ii) <i>Mutational Analysis of a Putative TRE</i>	151
5.2.5 Analysis of a Putative Ets Binding Site in the Human ALAS2 Promoter	151
i) <i>Gel Shift Analysis of a Putative Ets Site</i>	151
ii) <i>Mutational Analysis of a Putative Ets Binding Site</i>	152
5.3 DISCUSSION	153

**CHAPTER SIX : CHARACTERISATION OF AN ERYTHROID-SPECIFIC
ENHANCER LOCATED WITHIN INTRON 8 OF THE HUMAN ALAS2 GENE**

6.1 INTRODUCTION.....	163
6.2 RESULTS	163
6.2.1 Conservation of ALAS2 Intron 8 Sequence	163
6.2.2 Localisation of Erythroid-Specific Enhancer Activity to a 235 bp Fragment Within ALAS2 Intron 8	164
6.2.3 Identification of Functional Control Elements in Human ALAS2 Intron 8	166
6.2.4 GATA-1 Protein Binds to the Erythroid-Specific Enhancer in Human ALAS2 intron 8	167
6.2.5 Gel Shift Analysis of CACCC Sites Located Within Human ALAS2 Intron 8 ..	168
6.2.6 Attempts to Transactivate the Erythroid-Specific Intron 8 Enhancer in Non-Erythroid Cells	171
6.2.7 Intron 8 Enhancer Activity is not Modulated by a Non-Canonical TATA Box	172
6.3 DISCUSSION	173

CHAPTER SEVEN : FINAL DISCUSSION AND SUMMARY 183

REFERENCES 193

PUBLICATIONS

FORMAL PRESENTATIONS

THESIS SUMMARY

The focus of research in our laboratory has involved the elucidation of the regulatory mechanisms that control heme biosynthesis in eukaryotic cells. 5-aminolevulinate synthase (ALAS) is a nuclear encoded mitochondrial matrix enzyme that catalyses the formation of 5-aminolevulinate from glycine and succinyl CoA, the first step in the heme biosynthetic pathway. This enzyme is of particular interest since it is the rate-controlling enzyme. There are two closely related isozymes of ALAS designated ALAS1 and ALAS2 which are encoded by separate genes located on different chromosomes. The housekeeping enzyme, ALAS1 is probably expressed in all tissues to provide heme for respiratory cytochromes and other heme containing proteins. In contrast, ALAS2, is an erythroid-specific enzyme, the synthesis of which is developmentally regulated and is markedly increased during erythropoiesis to accommodate the increased demand for heme during hemoglobin production. Previous studies have demonstrated that expression of the ALAS2 gene is regulated at both the transcriptional and post-transcriptional levels.

During erythropoiesis, transcription of the ALAS2 gene is markedly upregulated together with the genes for the other heme pathway enzymes and for globin. The human ALAS2 gene consisting of 11 exons spanning 22 kb, and extensive 5' (10 kb) and 3' flanking (3 kb) sequence was previously isolated and sequenced in our laboratory. Comparison of the genomic organisation of the human and murine ALAS2 genes exhibit remarkable similarity. The work presented in this thesis is concerned with the identification of regulatory regions responsible for the transcriptional control of the human ALAS2 gene in erythroid cells. A number of regions of the human ALAS2 gene which corresponded to DNase I hypersensitivity sites in the murine ALAS2 gene were examined in transient expression studies performed in erythroid cell lines.

Deletion analysis of the 5'-flanking region of the human ALAS2 gene demonstrated that the first 300 bp upstream of the transcription initiation site could function as a promoter in erythroid cells. Putative binding sites for the erythroid-enriched transcription factors, GATA-1, NF-E2 and the CACCC box binding protein, EKLF, and ubiquitous transcription factors were identified in the ALAS2 promoter. Gel shift assays were performed to determine the proteins binding to these sites and the functional contribution of these sites evaluated by site-directed mutagenesis and transient expression analysis. However, ALAS2

promoter constructs containing -293 bp to -10.3 kb of 5'-flanking sequence also expressed efficiently in non-erythroid COS-1 cells indicating that additional sequence or native chromatin structure may be required for the erythroid-specific expression of the human ALAS2 gene *in vivo*.

Examination of other regions of the human ALAS2 gene which corresponded to DNase I hypersensitivity sites in the murine ALAS2 gene, resulted in the identification of an erythroid-specific enhancer element within intron 8, located approximately 16 kb downstream from the transcription initiation site. This enhancer element was capable of transactivating both the human ALAS2 promoter and the heterologous thymidine kinase promoter in erythroid cells. Sequence analysis of intron 8 revealed putative GATA and CACCC box motifs which are highly conserved between the human, murine and canine ALAS2 genes. Mutational analysis established that a combination of two CACCC boxes and one GATA-1 binding site was essential for activity of the erythroid-specific enhancer.

The association of GATA-1 and CACCC box binding sites have previously been reported to play a critical role in the tissue-specific expression of many other erythroid-specific genes, including the enzymes of the heme biosynthetic pathway and the globin gene cluster. The identification of functional GATA-1 and CACCC box binding sites in the human ALAS2 promoter and in the erythroid-specific enhancer element located within intron 8, highlights the importance of these transcription factors in the erythroid-specific regulation of erythroid-cell expressed genes. Consequently, an interaction of a common group of transcription factors within the regulatory regions of the genes encoding the enzymes of the heme biosynthetic pathway and the globin gene cluster would ensure the coordinated synthesis of heme molecules and globin chains during erythropoiesis.